QianJin Pharmaceutical(SH:600479) Ge Long Hui A P P·2025-10-13 09:55Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Fumaric Acid Vonoprazan Tablets (20mg, 10mg) from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1: Product Information - Fumaric Acid Vonoprazan Tablets are indicated for the treatment of reflux esophagitis and are used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori [1] - The product was developed by Takeda Pharmaceutical Company and was approved for sale in Japan in December 2014 under the brand name "Takecab" [1] - The product received approval for the Chinese market in December 2019 [1] Group 2: Market Potential - According to Morin Pharma data, the total sales of Fumaric Acid Vonoprazan Tablets in the domestic medical and retail market are projected to reach 532 million RMB by the first half of 2025 [1] Group 3: R&D Investment - As of the date of the announcement, Qianjin Pharmaceutical has invested a total of 15.1511 million RMB in the research and development of Fumaric Acid Vonoprazan Tablets [1]